Bifogade filer
PDF
Kurs
+1,38%
Likviditet
22,3 MSEK
Kalender
| Est. tid* | ||
| 2026-11-05 | 07:00 | Kvartalsrapport 2026-Q3 |
| 2026-07-15 | 07:00 | Kvartalsrapport 2026-Q2 |
| 2026-05-28 | N/A | Årsstämma |
| 2026-05-12 | 07:00 | Kvartalsrapport 2026-Q1 |
| 2026-02-12 | 07:00 | Bokslutskommuniké 2025 |
| 2025-11-06 | - | Kvartalsrapport 2025-Q3 |
| 2025-07-17 | - | Kvartalsrapport 2025-Q2 |
| 2025-05-28 | - | X-dag ordinarie utdelning CAMX 0.00 SEK |
| 2025-05-27 | - | Årsstämma |
| 2025-05-15 | - | Kvartalsrapport 2025-Q1 |
| 2025-02-13 | - | Bokslutskommuniké 2024 |
| 2024-11-07 | - | Kvartalsrapport 2024-Q3 |
| 2024-07-16 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-10 | - | X-dag ordinarie utdelning CAMX 0.00 SEK |
| 2024-05-08 | - | Årsstämma |
| 2024-05-08 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-15 | - | Bokslutskommuniké 2023 |
| 2023-11-09 | - | Kvartalsrapport 2023-Q3 |
| 2023-07-18 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-11 | - | X-dag ordinarie utdelning CAMX 0.00 SEK |
| 2023-05-10 | - | Årsstämma |
| 2023-05-10 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-14 | - | Bokslutskommuniké 2022 |
| 2022-11-10 | - | Kvartalsrapport 2022-Q3 |
| 2022-07-15 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-13 | - | X-dag ordinarie utdelning CAMX 0.00 SEK |
| 2022-05-12 | - | Årsstämma |
| 2022-05-12 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-16 | - | Bokslutskommuniké 2021 |
| 2021-11-04 | - | Kvartalsrapport 2021-Q3 |
| 2021-07-15 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-07 | - | X-dag ordinarie utdelning CAMX 0.00 SEK |
| 2021-05-06 | - | Årsstämma |
| 2021-05-06 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-11 | - | Bokslutskommuniké 2020 |
| 2020-11-05 | - | Kvartalsrapport 2020-Q3 |
| 2020-07-16 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-08 | - | X-dag ordinarie utdelning CAMX 0.00 SEK |
| 2020-05-07 | - | Årsstämma |
| 2020-05-07 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-12 | - | Bokslutskommuniké 2019 |
| 2019-11-08 | - | Kvartalsrapport 2019-Q3 |
| 2019-07-18 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-10 | - | X-dag ordinarie utdelning CAMX 0.00 SEK |
| 2019-05-09 | - | Årsstämma |
| 2019-05-09 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-06 | - | Bokslutskommuniké 2018 |
| 2018-10-25 | - | Kvartalsrapport 2018-Q3 |
| 2018-07-17 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-04 | - | X-dag ordinarie utdelning CAMX 0.00 SEK |
| 2018-05-03 | - | Årsstämma |
| 2018-05-03 | - | Kvartalsrapport 2018-Q1 |
| 2018-02-15 | - | Bokslutskommuniké 2017 |
| 2017-10-26 | - | Kvartalsrapport 2017-Q3 |
| 2017-07-13 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-04 | - | X-dag ordinarie utdelning CAMX 0.00 SEK |
| 2017-05-03 | - | Årsstämma |
| 2017-05-03 | - | Kvartalsrapport 2017-Q1 |
| 2017-02-16 | - | Bokslutskommuniké 2016 |
| 2016-10-22 | - | Kvartalsrapport 2016-Q3 |
| 2016-07-14 | - | Kvartalsrapport 2016-Q2 |
| 2016-05-17 | - | Kvartalsrapport 2016-Q1 |
| 2016-05-04 | - | X-dag ordinarie utdelning CAMX 0.00 SEK |
| 2016-05-03 | - | Årsstämma |
| 2016-03-30 | - | Bokslutskommuniké 2015 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Large Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
Lund, Sweden - 1 November 2023 - Camurus (Nasdaq Stockholm; CAMX), a commercial-stage pharmaceutical company developing innovative medications for severe and chronic diseases, today announced that Fredrik Tiberg, President and Chief Executive Officer, will participate in a fireside chat about the company's business progress and R&D pipeline developments at Jefferies 2023 Healthcare Conference in London on 15 November at 8:30-8:55 am local time (GMT).
A live webcast of the presentation can be accessed via: https://wsw.com/webcast/jeff287/camx.st/2248776
For more information
Fredrik Joabsson, Chief Business Development Officer
Tel. +46 (0)70 776 17 37
ir@camurus.com
About Camurus
Camurus is a Swedish, science-led biopharmaceutical company committed to developing and commercializing innovative, long-acting medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the company's proprietary FluidCrystal[®] drug delivery technologies and its extensive R&D expertise. Camurus' clinical pipeline includes products for the treatment of dependence, pain, cancer and endocrine diseases, which are developed in-house and in collaboration with international pharmaceutical companies. The company's shares are listed on Nasdaq Stockholm under the ticker CAMX. For more information, visit www.camurus.com.
This information was submitted for publication at 8:00 am CET on 1 November 2023.